About BioThera Solutions
BioThera Solutions is a publicly listed company based in Guangzhou (China) founded in 2003. The company has 1,250 employees. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Developer of antibody drugs to treat multiple diseases. The company focuses on the research and development of a new generation of antibody drugs for the treatment of tumors, autoimmune diseases, cardiovascular diseases, and other major diseases. The companys product portfolio includes Glarely (adalimumab), Pubexi (bevacizumab), Serelil (Tocilizumab), and more.
- Headquarters Guangzhou, China
- Employees 1,250
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website bio-thera.com
- Social LinkedIn X
- Legal Name Bio-Thera Solutions, Ltd. Class A
- Annual Revenue$133.2 M (USD)25.81as on Dec 31, 2025
- Net Profit-$47.41 M (USD)34.95as on Dec 31, 2025
- EBITDA-$43.22 M (USD)32.64as on Dec 31, 2025
- InvestorsHHS
& 1 more
- Employee Count1,250
Funding Insights of BioThera Solutions
- Total Rounds 4
- First Round $148,951
(Jun 2014)
- Investors Count 2
All 4 funding rounds of BioThera Solutions with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in BioThera Solutions
BioThera Solutions has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and gf.fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| gf.fund | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for BioThera Solutions
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of BioThera Solutions
BioThera Solutions is a publicly listed company on the SSE with ticker symbol 688177 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Feb 2020
- Listed onSSE: 688177
- Listed entityBio-Thera Solutions, Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE100003R98
- Share price17.43 CNY (-2.68% on the day) · 2026-10-14
- Market capitalisation7,416,172,496.00 CNY
- EPS (diluted, trailing year)-1.11 CNY
- Volume (last session)2,919,829
Financials of BioThera Solutions
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 932.5M CNY | -331.9M CNY | -302.6M CNY |
| 2024 | 741.2M CNY | -510.3M CNY | -449.1M CNY |
| 2023 | 703.0M CNY | -394.5M CNY | -379.6M CNY |
| 2022 | 454.5M CNY | -480.4M CNY | -441.4M CNY |
| 2021 | 834.4M CNY | 81.9M CNY | 125.5M CNY |
Detailed financial statements for BioThera Solutions
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BioThera Solutions
4 dated milestones of BioThera Solutions across 17 years, from founding to its latest funding, stage changes and deals.
- Founded BioThera Solutions is founded.
- Funding First funding round of $149K.
- Funding Latest funding round, Series C,.
- IPO Lists on the stock exchange (IPO).
Web traffic of BioThera Solutions
The website of BioThera Solutions (bio-thera.com) receives about 1.4K visits a month and ranks #6,055,597 among all websites worldwide, #6,393 in Biotechnology and Pharmaceuticals.
- Monthly visits1.4K
▼ 49.6% vs previous month
- Unique visitors1.1K
per month
- Global rank#6,055,597
among all websites
- Category rank#6,393
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit45 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with BioThera Solutions. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stada.com | 100% | 79.7K | #482,860 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biothera Solutions
Complete news archive for BioThera Solutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioThera Solutions
BioThera Solutions was founded in 2003 and raised its 1st funding round 11 years after it was founded.
BioThera Solutions is headquartered in Guangzhou, China. It is registered at Guangzhou, Guangdong, China.
BioThera Solutions has 1,250 employees.
Annual revenue of BioThera Solutions is $133.2M as on Dec 31, 2025.
Developer of antibody drugs to treat multiple diseases. The company focuses on the research and development of a new generation of antibody drugs for the treatment of tumors, autoimmune diseases, cardiovascular diseases, and other major diseases. The companys product portfolio includes Glarely (adalimumab), Pubexi (bevacizumab), Serelil (Tocilizumab), and more.
Yes, BioThera Solutions is publicly traded on SSE under the ticker symbol 688177.
BioThera Solutions has 2 investors. Key investors include HHS, and gf.fund.